Volatile organic compounds in breath as marker of asthma and COPD: studies on methodologic aspects

Volatile organic compounds in breath as marker of asthma and COPD: studies on methodologic aspects - VOC in breath: methodological aspects

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON31214

Enrollment

150

Registered

2007-09-10

Start date

2007-09-01

Completion date

Unknown

Last updated

2024-08-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

airway obstruction COPD

Interventions

Study 1 smoking a cigarette Study 2 intranasal oxygen supply (20 minutes 3 litres/minute) study 3 nebulisation with salbutamol/ipartropiumbromide ( 2,5/0,5 microgram)

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Study 1;COPD patients: •Adults between 40-65 years •Lungfunction: FEV1/VC10 cigarettes/day, >10 packyears) Controls: •Adults between 40-65 years •Healthy with a negative history on lung diseases or any other illness. •Prebronchodilator FEV1 > 80% predicted, FEV1/FVC > 0.70 (22) •Actual smoker(>10 cigarettes/day, > 10 packyears);Study 2;COPD patients: •Adults between 40-65 years •Lungfunction: FEV1/VC 1 year, > 10 packyears) Controls: •Adults between 40-65 years •Healthy with a negative history on lung diseases or any other illness. •Prebronchodilator FEV1 > 80% predicted, FEV1/FVC > 0.70 (22) •Actual non-smoker(> 1 year);Study 3;COPD patients: •Adults between 40-65 years •Lungfunction: FEV1/VC1 year, > 10 packyears) Asthma patients: •Adults between 40-65 years •episodic chest symptoms, documented reversibility in FEV1 by 400 µg inhaled salbutamol > 12 %pred or airway hyperresponsiveness (PC20 methacholine 1 year,

Exclusion criteria

Exclusion criteria: •Other pulmonary diseases •Pregnancy •Diabetes mellitus (documented in the past) •Hypercholesterolaemia (documented in the past) •Exacerbation

Design outcomes

Primary

Measure	Time frame
Study 1: the change in smellprint before and after smoking a cigarette. Study 2: the change in smellprint before, during and after oxygen supply Study 3: the change in smellprint before and after nebulisation of salbutamol/ipratropiumbromide	—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)